Skip to main content
Tourmaline Bio, Inc. logo

Tourmaline Bio, Inc. — Investor Relations & Filings

Ticker · TRML ISIN · US87410C1045 US Manufacturing
Open in API
Filings indexed 336 across all filing types
Latest filing 2024-08-08 Earnings Release
Country US United States of America
Listing US TRML

About Tourmaline Bio, Inc.

https://www.tourmalinebio.com/

Tourmaline Bio, Inc. is a late-stage clinical biotechnology company focused on developing transformative medicines for patients with life-altering inflammatory and immune diseases. The company's lead asset is pacibekitug, a monoclonal antibody that targets the interleukin-6 (IL-6) cytokine, a key driver of inflammation. Pacibekitug is being developed as a potential treatment for a range of conditions, with a primary focus on atherosclerotic cardiovascular disease (ASCVD) and other severe autoimmune and inflammatory disorders, aiming to establish a new standard of care in areas with high unmet medical need.

Recent filings

Filing Released Lang Actions
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 8, 2024, reporting the issuance of a press release announcing business highlights and financial results for the quarter ended June 30, 2024. The text explicitly states that the press release is furnished as Exhibit 99.1 and incorporated by reference, and that the information is being furnished and not filed, indicating this is an announcement of results rather than the full earnings report itself. The document length is 3959 characters, which is relatively short and consistent with a Form 8-K filing announcing earnings results rather than containing detailed financial statements. The key section is Item 2.02 "Results of Operations and Financial Condition," which is typically used for earnings releases. Therefore, this document is best classified as an Earnings Release (ER).
2024-08-08 English
FORM 4
Director's Dealing
2024-06-27 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated June 25, 2024, reporting the appointment of Ryan Robinson as Chief Financial Officer and Treasurer of Tourmaline Bio, Inc. The content focuses on management changes, including biographical details, compensation, and related agreements. There is no financial data or report attached, nor is it an announcement of a report publication. The primary subject is a change in senior management, which fits the category of Board/Management Information (MANG).
2024-06-27 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K current report filed with the SEC, dated June 5, 2024, reporting the submission of matters to a vote of security holders at the company's 2024 annual meeting. It details the voting results for the election of directors and ratification of the independent auditor. The content focuses on the official results of shareholder votes at the annual meeting, including vote counts and outcomes. This matches the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA). The document is not an annual report, earnings release, or management discussion, but specifically a report of voting results from the AGM. The length and detail confirm it is the voting results report itself, not just an announcement of a report. Therefore, the correct classification is DVA with high confidence.
2024-06-07 English
FORM 4
Director's Dealing
2024-06-07 English
FORM 4
Director's Dealing
2024-06-07 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.